Q2 2026 Hikal Ltd Earnings Call Transcript
Key Points
- Hikal Ltd (BOM:524735) reported a consolidated revenue of INR319 crores for Q2 FY26, indicating operational stability despite external challenges.
- The company has onboarded two global remediation partners to strengthen internal quality systems, ensuring corrective actions meet global standards.
- Hikal Ltd (BOM:524735) is witnessing significant traction from key global innovators, strengthening its future pipeline of complex chemistry molecules.
- The company is expanding its collaboration with global customers in the Personal Care division, expecting to commercialize two to three products in the second half of the financial year.
- Hikal Ltd (BOM:524735) inaugurated a state-of-the-art high-potency laboratory, enhancing capabilities in high-potency molecule development, reflecting a commitment to innovation and long-term growth.
- The Pharmaceutical business faced disruptions due to regulatory developments, resulting in an EBIT margin of negative 9.2% for the quarter.
- Hikal Ltd (BOM:524735) received a warning letter from the USFDA, delaying the offtake across generics and CDMO businesses.
- The Crop Protection segment recorded an EBIT of minus INR10 crores, with margins under pressure due to ongoing pricing challenges from oversupply.
- The company's financial performance in the CDMO business remains muted as innovator customers undergo business segment restructuring and destocking.
- Hikal Ltd (BOM:524735) experienced a short-term deferral of sales in the Pharmaceutical business, affecting financials due to underabsorption of fixed costs.
Ladies and gentlemen, good day, and welcome to Q2 FY26 earnings conference call of Hikal Limited. This conference call may contain forward-looking statements about the company, which are based on beliefs, opinions and expectations of the company as on the date of this call. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Mr. Sameer Hiremath, Vice Chairman and Managing Director from Hikal Limited. Thank you, and over to you, sir.
Thank you. Ladies and gentlemen, good afternoon, and a warm welcome to all of you. We extend our gratitude to all of you for participating in our Q2 and H1 FY26 results conference call. We are pleased to provide you with an update on the progress made by our company. We trust you have had the opportunity to review our comprehensive earnings release,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
